OA10221A - Oligonucléotides pour inhiber le rôle des isoprényl protéine transférases - Google Patents

Oligonucléotides pour inhiber le rôle des isoprényl protéine transférases Download PDF

Info

Publication number
OA10221A
OA10221A OA60679A OA60679A OA10221A OA 10221 A OA10221 A OA 10221A OA 60679 A OA60679 A OA 60679A OA 60679 A OA60679 A OA 60679A OA 10221 A OA10221 A OA 10221A
Authority
OA
OAPI
Prior art keywords
seq
sequence
oligonucleotides
nucleotide
type
Prior art date
Application number
OA60679A
Other languages
English (en)
French (fr)
Inventor
Colote Soudhir
Pirotzky Eduardo
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of OA10221A publication Critical patent/OA10221A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y205/00Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01029Geranylgeranyl diphosphate synthase (2.5.1.29)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
OA60679A 1994-06-29 1995-06-29 Oligonucléotides pour inhiber le rôle des isoprényl protéine transférases OA10221A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9413035A GB9413035D0 (en) 1994-06-29 1994-06-29 Antisense oligonucleeotides

Publications (1)

Publication Number Publication Date
OA10221A true OA10221A (fr) 1997-09-19

Family

ID=10757497

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60679A OA10221A (fr) 1994-06-29 1995-06-29 Oligonucléotides pour inhiber le rôle des isoprényl protéine transférases

Country Status (25)

Country Link
US (1) US5856461A (cs)
EP (1) EP0692535A1 (cs)
JP (1) JPH0851985A (cs)
KR (1) KR960000914A (cs)
CN (1) CN1124142A (cs)
AU (1) AU689887B2 (cs)
BR (1) BR9503015A (cs)
CA (1) CA2152233A1 (cs)
CZ (1) CZ291496B6 (cs)
DZ (1) DZ1903A1 (cs)
FI (1) FI953170A7 (cs)
FR (2) FR2721827A1 (cs)
GB (2) GB9413035D0 (cs)
HU (1) HU219823B (cs)
IE (1) IE950477A1 (cs)
MA (1) MA23595A1 (cs)
NO (1) NO952601L (cs)
NZ (1) NZ272398A (cs)
OA (1) OA10221A (cs)
PL (1) PL309384A1 (cs)
RU (1) RU2112766C1 (cs)
SE (1) SE9502259L (cs)
SK (1) SK83895A3 (cs)
TN (1) TNSN95068A1 (cs)
ZA (1) ZA955288B (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226623A1 (en) * 1995-07-13 1997-01-30 University Of Cincinnati Compounds useful in the treatment of neurofibromatosis
CN1301731A (zh) * 1999-12-24 2001-07-04 上海博德基因开发有限公司 一种新的多肽——多异戊二烯基合成酶蛋白9和编码这种多肽的多核苷酸
US20030157598A1 (en) * 2000-12-07 2003-08-21 Ramanathan Chandra S. Novel human G-protein coupled receptor, HGPRBMY23, expressed highly in kidney
RU2224524C2 (ru) * 2002-03-29 2004-02-27 Некоммерческое партнерство "АСГЛ - Исследовательские лаборатории" Олигонуклеотиды для подавления жизнедеятельности патогенных микроорганизмов и способ подавления их жизнедеятельности
US20030212017A1 (en) * 2002-05-10 2003-11-13 Isis Pharmaceuticals Inc. Antisense modulation of farnesyl transferase beta subunit expression
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
PL1667522T3 (pl) 2003-09-09 2018-06-29 Geron Corporation Zmodyfikowane oligonukleotydy do hamowania telomerazy
US8785409B2 (en) * 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4571421A (en) * 1979-11-05 1986-02-18 Genentech, Inc. Mammalian gene for microbial expression
US5004803A (en) * 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
US5420245A (en) * 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
US5185248A (en) * 1990-05-08 1993-02-09 E. R. Squibb & Sons, Inc. Farnesyl-protein transferase assay for identifying compounds that block neoplastic transformation
DE69233158T2 (de) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
NZ244820A (en) * 1991-10-25 1994-01-26 Isis Pharmaceuticals Inc Oligonucleotide inhibitor of epstein-barr virus.
US5348853A (en) * 1991-12-16 1994-09-20 Biotronics Corporation Method for reducing non-specific priming in DNA amplification
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA

Also Published As

Publication number Publication date
SE9502259D0 (sv) 1995-06-21
AU689887B2 (en) 1998-04-09
FR2721930B1 (fr) 1997-01-03
BR9503015A (pt) 1996-06-04
IE950477A1 (en) 1996-01-10
FI953170L (fi) 1995-12-30
GB9513246D0 (en) 1995-09-06
MA23595A1 (fr) 1995-12-31
NZ272398A (en) 1996-04-26
ZA955288B (en) 1996-01-31
SK83895A3 (en) 1996-05-08
HU9501913D0 (en) 1995-08-28
CZ291496B6 (cs) 2003-03-12
SE9502259L (sv) 1995-12-30
CZ168895A3 (en) 1996-05-15
AU2329995A (en) 1996-01-11
EP0692535A1 (fr) 1996-01-17
CN1124142A (zh) 1996-06-12
HUT72133A (en) 1996-03-28
PL309384A1 (en) 1996-01-08
FR2721930A1 (fr) 1996-01-05
GB2290791B (en) 1998-08-05
GB9413035D0 (en) 1994-08-17
NO952601L (no) 1996-01-02
NO952601D0 (no) 1995-06-28
RU2112766C1 (ru) 1998-06-10
TNSN95068A1 (fr) 1996-02-06
KR960000914A (ko) 1996-01-25
DZ1903A1 (fr) 2002-02-17
US5856461A (en) 1999-01-05
FI953170A0 (fi) 1995-06-27
FI953170A7 (fi) 1995-12-30
CA2152233A1 (en) 1995-12-30
JPH0851985A (ja) 1996-02-27
FR2721827A1 (fr) 1996-01-05
RU95110774A (ru) 1997-04-20
HU219823B (hu) 2001-08-28
GB2290791A (en) 1996-01-10

Similar Documents

Publication Publication Date Title
CA2222197A1 (fr) Oligonucleotides antisens pour bloquer la synthese du recepteur de l'ige
JP4643906B2 (ja) 遺伝子発現の標的化阻害のための合成二本鎖オリゴヌクレオチド
EP0736093B1 (en) ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB-2 PLAYS A ROLL
CA2882443C (en) Rnai probes targeting cancer-related proteins
JPH09507502A (ja) raf遺伝子発現のアンチセンスオリゴヌクレオチド調節
JP2000509259A (ja) 血管内皮増殖因子(VEgF/VPF)発現のアンチセンス阻害剤
CA2795145A1 (en) Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
JPH11501509A (ja) t(14:18)転座を有する腫瘍細胞に関連するアンチセンス転写産物とこの腫瘍細胞の診断及び治療に有用なオリゴデオキシヌクレオチド
JPH08505397A (ja) 平滑筋細胞の増殖を調節するためのc‐mycのアンチセンス阻害
JPH10508760A (ja) raf遺伝子発現のアンチセンスオリゴヌクレオチド調節
EP3061824B1 (en) Organic compositions to treat beta-enac-related diseases
OA10221A (fr) Oligonucléotides pour inhiber le rôle des isoprényl protéine transférases
EP0815217A1 (fr) Oligonucleotides antisens pour inhiber le role de l'helicobacter pylori
Chiarantini et al. Comparison of novel delivery systems for antisense peptide nucleic acids
TW390884B (en) Chirally enriched synthetic phosphonate oligomers
KR102061924B1 (ko) P32 저해제를 포함하는 심혈관 질환 예방 또는 치료용 조성물
JPH07508977A (ja) インターロイキン−1の阻害による細胞の過剰増殖の処置
Epa et al. Enhanced downregulation of the p75 nerve growth factor receptor by cholesteryl and bis-cholesteryl antisense oligonucleotides
JP4690649B2 (ja) 標的化された遺伝子発現阻害のための新規なオリゴリボヌクレオチド誘導体
JP2000506866A (ja) アンギオテンシノゲンmRNAに標的化されたオリゴヌクレオチド
US20210214727A1 (en) Enhanced oligonucleotides for inhibiting scn9a expression
KR20010042796A (ko) 인테그린 αv-아단위 발현 억제를 위한 안티센스올리고뉴클레오티드
WO2024251725A1 (en) Oligonucleotides targeting gal3st1
WO2025240886A1 (en) Patterned double stranded oligonucleotides
WO2003059394A1 (fr) Compositions pour la vectorisation d'oligonucleotides a travers la barriere hematoencephalique et leur utilisatin pour le traitement des maladies du systeme nerveux central